Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

Digitek Information

What is Digitek?

Digitek (digoxin tablets) is used in the treatment of congestive heart failure and other heart problems. It improves the strength and efficiency of your heart, leading to better circulation of blood and reduction of the uncomfortable swelling that is common in people with congestive heart failure.

In April 2008, Actavis Totowa LLC notified healthcare professionals of a Class I nationwide recall of all strengths of Digitek due to the possibility that tablets with double the appropriate thickness may contain twice the approved level of active ingredient. If taken inadvertently, the double dose poses a risk of ditigalis toxicity, especially in patients with renal failure. Digitalis toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instabililty, and bradycardia (slow heart rate).

Digitek MDL (Multidistrict Litigation) Assigned To Southern District Of West Virginia
All pending Digitek cases and all future Digitek lawsuits filed in the federal court system will be centralized for discovery purposes in the Southern District of West Virginia before Judge Joseph R. Goodwin, in the case captioned In Re: Digitek Products Liability Litigation, MDL No. 1968, JPMDL.


FDA Issues Digitek Recall In April 2008 Because Defective Tablets Are Too Potent
On April 28, 2008 a MedWatch Safety Alert about Digitek (digoxin tablets) was issued by the FDA announcing a nationwide Class I recall of all lots of Digitek pills distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label. Digitek is usually prescribed for the treatment of arrhythmias and heart failure.


A Week After Heart Drug Manufacturing Problem Is Announced, Pharmacist Says Digitek Recall Facts Remain "Sketchy"
A May 2, 2008 interview with local pharmacist Mark McKenzie by NBC affiliate KSDK in St. Louis, Missouri, included an observation that some important facts surrounding a late April 2008 recall of Digitek (digoxin) pills are less than clear one week afterwards. In his interview, pharmacist McKenzie characterized the currently available information about this Digitek recall as "sketchy" even though, in his estimation, the defective pills presented an "immediate" problem which deserved immediate action.


Digitek and Legal Compensation
Legal compensation claims involving a Digitek adverse side effect or death are best made by filing an individual lawsuit as opposed to a class action. All states have statutes of limitations that determine the time period allowed to file a Digitek lawsuit. The applicable statute of limitation, or deadline to file claims, varies from state to state, and the personal injury statute of limitation deadline can be different from the wrongful death statute of limitation deadline within the same state.


Digitek Class Actions
We believe that people who had a serious Digitek injury or suffered a death due to Digitek toxicity are better served when an individual lawsuit is filed on their behalf.



Free Digitek Case Evaluation
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential.  You will get a reply from us no later than the next business day.  Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit.  We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.

Drug Injury Watch: Digitek News Commentary


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer